AstraZeneca's Tagrisso, in combination with pemetrexed and platinum-based chemotherapy, has shown a significant improvement ...

In the real-world trial, Novo Nordisk's Wegovy showed a significant reduction in CV events compared to Eli Lilly’s Zepbound.

Alnylam has disclosed new analysis findings from the HELIOS-B Phase III clinical trial of RNA interference (RNAi) therapeutic ...

As the IASLC 2025 World Conference on Lung Cancer approaches, CTA looks at some of the most promising NSCLC assets in Phase ...

RealTime eClinical Solutions has rolled out the TrialAlign platform that aims to refine the performance analytics for ...

Researchers at the UQ's AIBN have received approval for a trial to examine a heart medication in treating amyotrophic lateral ...

As Western biotechs struggle with financing, China emerges as a dominant force in the CGT trial space. In 2019, the number of ...

If approved, Regeneron's siRNA therapy will join the myasthenia gravis market alongside AstraZeneca’s dominant drugs ...

Eli Lilly’s CDK4/6 inhibitor Verzenio (abemaciclib) has been shown to improve overall survival (OS) in early, high-risk, HR+ ...

This Phase II data keeps Upstream Bio's verekitug in contention with AstraZeneca and Amgen’s Teszpire in terms of efficacy.

WCG has introduced Total Training, a clinical trial solution designed to reduce protocol deviations and enhance site ...

Amgen has entered into a partnership to use Veeva Systems’ comprehensive Clinical Platform to enhance trial processes.